Categories: News

H Robotics selected to exhibit at the MedTech Innovator Road Tour!

The rehabilitation innovators will present rebless™, an FDA-registered robotic therapy device for both upper and lower extremities.

AUSTIN, Texas, May 9, 2022 /PRNewswire-PRWeb/ — It is with great pride that we announce that we have been selected to exhibit our state-of-the-art rehabilitative device, rebless™, during the MedTech Innovator Road Tour in Boston, MA next week. Out of more than 1,000 companies that applied, H Robotics was selected as one of 22 startups to exhibit in Boston. rebless™, an FDA-registered robotic, therapy device for both the upper and lower extremity.

The device features multiple operating modes, allowing for active-assisted range of motion, resisted motion, and passive range of motion. With its smart tele-rehab technology, rebless clinic™, clinicians can perform telehealth video sessions, and customize treatment plans based on a patient’s condition and progress, for the patient to perform either in the clinic or in the comfort of their own home. Not only does rebless™ improve patient compliance, but it also has proven to increase clinician efficiency, productivity, and overall clinical revenue.

The mission of H Robotics Inc. is to give everyone a chance to rehabilitate and improve their quality of life. We aim to contribute to a healthier life for all mankind through innovative technology. Our selection to exhibit in Boston serves as just one example of how our company is continuing to grow and contribute to the healthcare community.

If you would like to learn more about our company, our device, or request a trial with rebless™, please visit us at http://www.hroboticsus.com or email us at contact@hroboticsus.com.

Media Contact

Andrew Chang, H Robotics, 1 512-634-3636, info@hroboticsus.com

 

SOURCE H Robotics

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

5 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

6 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

6 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

7 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

8 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

9 hours ago